Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.

Makoto Nishio Shuji Murakami Hiasto Kawakami Kyoichi Okishio Motohiro Tamiya Haruki Kobayashi Daichi Fujimoto Shunichi Sugawara Toshiyuki Kozuki Yuko Oya Hiroki Izumi Takayuki Shiroyama Miyako Satouchi Noboru Yamamoto Shota Kaname Daiko Matsuoka Yohei Otake Takao Takase Taro Semba Koichi Azuma

Published in: Cancer research communications (2024)

E7389-LF 2.1mg/m2 in combination with nivolumab 360mg Q3W showed notable antitumor activity as second-line therapy for SCLC; no new safety signals were observed compared to either agent as monotherapy.

Keyphrases

small cell lung cancer
open label
drug delivery
phase ii
metastatic breast cancer
clinical trial
randomized controlled trial
brain metastases
study protocol